Inhibition of Kaposi's sarcoma-associated herpesvirus lytic replication by HIV-1 Nef and cellular MicroRNA hsa-miR-1258

Journal of Virology

Volumn 88, Issue 9, 2014, Pages 4987-5000

  Yan, Qin ^a   Ma, Xinting ^a   Shen, Chenyou ^a   Cao, Xu ^a,b   Feng, Ninghan ^a,b   Qin, Di ^a   Zeng, Yi ^c   Zhu, Jianzhong ^d   Gao, Shou Jiang ^e   Lu, Chun ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c YOUJIANG MEDICAL COLLEGE FOR NATIONALITIES   (China)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; MESSENGER RNA; MICRORNA; MICRORNA 1258; NEF PROTEIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; DOWN REGULATION; GENE REPRESSION; GENE TARGETING; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; INTERNALIZATION; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; VIROGENESIS; VIRUS EXPRESSION; VIRUS INHIBITION; VIRUS LATENCY; VIRUS PARTICLE; VIRUS REACTIVATION; VIRUS REPLICATION;

GENE EXPRESSION PROFILING; HERPESVIRUS 8, HUMAN; HIV-1; HUMANS; MICROARRAY ANALYSIS; MICRORNAS; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRAL INTERFERENCE; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84897524554     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00025-14     Document Type: Article

References (92)

1. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-1869. http://dx.doi.org/10.1126/science.7997879.
2. Mbulaiteye SM, Katabira ET, Wabinga H, Parkin DM, Virgo P, Ochai R, Workneh M, Coutinho A, Engels EA. 2006. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int. J. Cancer 118:985-990. http://dx.doi.org/10.1002/ijc.21443.
3. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N. Engl. J. Med. 332:1186-1191. http://dx.doi.org/10.1056/NEJM199505043321802.
4. Dittmer DP, Damania B. 2007. KSHV-associated disease in the AIDS patient. Cancer Treatment Res. 133:129-139. http://dx.doi.org/10.1007/978-0-387-46816-7_4.
5. Blum L, Pellet C, Agbalika F, Blanchard G, Morel P, Calvo F, Lebbe C. 1997. Complete remission of AIDS-related Kaposi's sarcoma associated with undetectable human herpesvirus-8 sequences during anti-HIV protease therapy. AIDS 11:1653-1655.
6. Strathdee SA, Veugelers PJ, Moore PS. 1996. The epidemiology of HIVassociated Kaposi's sarcoma: the unraveling mystery. AIDS 10(Suppl A): S51-S57.
7. Ganem D. 2006. KSHV infection and the pathogenesis of Kaposi's sarcoma. Annu. Rev. Pathol. 1:273-296. http://dx.doi.org/10.1146/annurev.pathol.1.110304.100133.
8. Mocroft A, Youle M, Phillips AN, Halai R, Easterbrook P, Johnson MA, Gazzard B. 1998. The incidence of AIDS-defining illnesses in 4883 patients with human immunodeficiency virus infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. Arch. Intern. Med. 158: 491-497.
9. Delli Bovi P, Donti E, Knowles DM, Jr, Friedman-Kien A, Luciw PA, Dina D, Dalla-Favera R, Basilico C. 1986. Presence of chromosomal abnormalities and lack of AIDS retrovirus DNA sequences in AIDSassociated Kaposi's sarcoma. Cancer Res. 46:6333-6338.
10. Fiorelli V, Gendelman R, Samaniego F, Markham PD, Ensoli B. 1995. Cytokines from activatedTcells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells. J. Clin. Investig. 95:1723-1734. http://dx.doi.org/10.1172/JCI117849.
11. Mercader M, Taddeo B, Panella JR, Chandran B, Nickoloff BJ, Foreman KE. 2000. Induction of HHV-8 lytic cycle replication by inflammatory cytokines produced by HIV-1-infected T cells. Am. J. Pathol. 156:1961-1971. http://dx.doi.org/10.1016/S0002-9440(10)65069-9.
12. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, Wingfield P, Gallo RC. 1993. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J. Virol. 67:277-287.
13. Ensoli B, Cafaro A. 1996. HIV-1 and Kaposi's sarcoma. Eur. J. Cancer Prev. 5:410-412.
14. Harrington W, Jr, Sieczkowski L, Sosa C, Chan-a-Sue S, Cai JP, Cabral L, Wood C. 1997. Activation of HHV-8 by HIV-1 tat. Lancet 349:774-775.
15. Zeng Y, Zhang X, Huang Z, Cheng L, Yao S, Qin D, Chen X, Tang Q, Lv Z, Zhang L, Lu C. 2007. Intracellular Tat of human immunodeficiency virus type 1 activates lytic cycle replication of Kaposi's sarcoma-associated herpesvirus: role of JAK/STAT signaling. J. Virol. 81:2401-2417. http://dx.doi.org/10.1128/JVI.02024-06.
16. Guo HG, Pati S, Sadowska M, Charurat M, Reitz M. 2004. Tumorigenesis by human herpesvirus 8 vGPCR is accelerated by human immunodeficiency virus type 1 Tat. J. Virol. 78:9336-9342. http://dx.doi.org/10.1128/JVI.78.17.9336-9342.2004.
17. Chen X, Cheng L, Jia X, Zeng Y, Yao S, Lv Z, Qin D, Fang X, Lei Y, Lu C. 2009. Human immunodeficiency virus type 1 Tat accelerates Kaposi sarcoma-associated herpesvirus Kaposin A-mediated tumorigenesis of transformed fibroblasts in vitro as well as in nude and immunocompetent mice. Neoplasia 11:1272-1284. http://www.neoplasia.com/pdf/manuscript/v11i12/neo09494.pdf.
18. Kestler HW, III, Ringler DJ, Mori K, Panicali DL, Sehgal PK, Daniel MD, Desrosiers RC. 1991. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65:651-662. http://dx.doi.org/10.1016/0092-8674(91)90097-I.
19. Raymond AD, Campbell-Sims TC, Khan M, Lang M, Huang MB, Bond VC, Powell MD. 2011. HIV type 1 Nef is released from infected cells in CD45(+) microvesicles and is present in the plasma of HIV-infected individuals. AIDS Res. Hum. Retrovir. 27:167-178. http://dx.doi.org/10.1089/aid.2009.0170.
20. Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G, Bonnerot C. 2005. Exosomal-like vesicles are present in human blood plasma. Int. Immunol. 17:879-887. http://dx.doi.org/10.1093/intimm/dxh267.
21. Guy B, Kieny MP, Riviere Y, Le Peuch C, Dott K, Girard M, Montagnier L, Lecocq JP. 1987. HIV F/3' orf encodes a phosphorylated GTPbinding protein resembling an oncogene product. Nature 330:266-269. http://dx.doi.org/10.1038/330266a0.
22. Fujii Y, Otake K, Tashiro M, Adachi A. 1996. Soluble Nef antigen of HIV-1 is cytotoxic for human CD4+ T cells. FEBS Lett. 393:93-96. http://dx.doi.org/10.1016/0014-5793(96)00859-9.
23. Guy B, Riviere Y, Dott K, Regnault A, Kieny MP. 1990. Mutational analysis of the HIV nef protein. Virology 176:413-425. http://dx.doi.org/10.1016/0042-6822(90)90011-F.
24. Macreadie IG, Fernley R, Castelli LA, Lucantoni A, White J, Azad A. 1998. Expression of HIV-1 nef in yeast causes membrane perturbation and release of the myristylated Nef protein. J. Biomed. Sci. 5:203-210.
25. Cullen BR. 1998. HIV-1 auxiliary proteins: making connections in a dying cell. Cell 93:685-692. http://dx.doi.org/10.1016/S0092-8674(00)81431-2.
26. Qiao X, He B, Chiu A, Knowles DM, Chadburn A, Cerutti A. 2006. Human immunodeficiency virus 1 Nef suppresses CD40-dependent im-munoglobulin class switching in bystander B cells. Nat. Immunol. 7:302-310. http://dx.doi.org/10.1038/ni1302.
27. Xu W, Santini PA, Sullivan JS, He B, Shan M, Ball SC, Dyer WB, Ketas TJ, Chadburn A, Cohen-Gould L, Knowles DM, Chiu A, Sanders RW, Chen K, Cerutti A. 2009. HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. Nat. Immunol. 10:1008-1017. http://dx.doi.org/10.1038/ni.1753.
28. Moir S, Fauci AS. 2010. Nef, macrophages and B cells: a highway for evasion. Immunol. Cell Biol. 88:1-2. http://dx.doi.org/10.1038/icb.2009.82.
29. Greenway AL, McPhee DA, Allen K, Johnstone R, Holloway G, Mills J, Azad A, Sankovich S, Lambert P. 2002. Human immunodeficiency virus type 1 Nef binds to tumor suppressor p53 and protects cells against p53-mediated apoptosis. J. Virol. 76:2692-2702. http://dx.doi.org/10.1128/JVI.76.6.2692-2702.2002.
30. Smith BL, Krushelnycky BW, Mochly-Rosen D, Berg P. 1996. The HIV nef protein associates with protein kinase C theta. J. Biol. Chem. 271: 16753-16757. http://dx.doi.org/10.1074/jbc.271.28.16753.
31. Wolf D, Witte V, Laffert B, Blume K, Stromer E, Trapp S, d'Aloja P, Schurmann A, Baur AS. 2001. HIV-1 Nef associated PAK and PI3-kinases stimulate Akt-independent Bad-phosphorylation to induce antiapoptotic signals. Nat. Med. 7:1217-1224. http://dx.doi.org/10.1038/nm1101-1217.
32. Greenway A, Azad A, Mills J, McPhee D. 1996. Human immunodeficiency virus type 1 Nef binds directly to Lck and mitogen-activated protein kinase, inhibiting kinase activity. J. Virol. 70:6701-6708.
33. Saksela K, Cheng G, Baltimore D. 1995. Proline-rich (PxxP) motifs in HIV-1 Nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth of Nef+ viruses but not for down-regulation of CD4. EMBO J. 14:484-491.
34. Cheng H, Hoxie JP, Parks WP. 1999. The conserved core of human immunodeficiency virus type 1 Nef is essential for association with Lck and for enhanced viral replication in T-lymphocytes. Virology 264:5-15. http://dx.doi.org/10.1006/viro.1999.9937.
35. Dutartre H, Harris M, Olive D, Collette Y. 1998. The human immunodeficiency virus type 1 Nef protein binds the Src-related tyrosine kinase Lck SH2 domain through a novel phosphotyrosine independent mechanism. Virology 247:200-211. http://dx.doi.org/10.1006/viro.1998.9244.
36. Mangino G, Percario ZA, Fiorucci G, Vaccari G, Manrique S, Romeo G, Federico M, Geyer M, Affabris E. 2007. In vitro treatment of human monocytes/macrophages with myristoylated recombinant Nef of human immunodeficiency virus type 1 leads to the activation of mitogenactivated protein kinases, IkappaB kinases, and interferon regulatory factor 3 and to the release of beta interferon. J. Virol. 81:2777-2791. http://dx.doi.org/10.1128/JVI.01640-06.
37. Brigino E, Haraguchi S, Koutsonikolis A, Cianciolo GJ, Owens U, Good RA, Day NK. 1997. Interleukin 10 is induced by recombinant HIV-1 Nef protein involving the calcium/calmodulin-dependent phosphodiesterase signal transduction pathway. Proc. Natl. Acad. Sci. U. S. A. 94:3178-3182. http://dx.doi.org/10.1073/pnas.94.7.3178.
38. Tobiume M, Fujinaga K, Suzuki S, Komoto S, Mukai T, Ikuta K. 2002. Extracellular Nef protein activates signal transduction pathway from Ras to mitogen-activated protein kinase cascades that leads to activation of human immunodeficiency virus from latency. AIDS Res. Hum. Retrovir. 18:461-467. http://dx.doi.org/10.1089/088922202753614227.
39. Varin A, Manna SK, Quivy V, Decrion AZ, Van Lint C, Herbein G, Aggarwal BB. 2003. Exogenous Nef protein activates NF-kappa B, AP-1, and c-Jun N-terminal kinase and stimulates HIV transcription in promonocytic cells. Role in AIDS pathogenesis. J. Biol. Chem. 278:2219-2227. http://dx.doi.org/10.1074/jbc.M209622200.
40. Zhu X, Guo Y, Yao S, Yan Q, Xue M, Hao T, Zhou F, Zhu J, Qin D, Lu C. 22 April 2013. Synergy between Kaposi's sarcoma-associated herpesvirus (KSHV) vIL-6 and HIV-1 Nef protein in promotion of angiogenesis and oncogenesis: role of the AKT signaling pathway. Oncogene. http://dx.doi.org/10.1038/onc.2013.136.
41. Cai X, Lu S, Zhang Z, Gonzalez CM, Damania B, Cullen BR. 2005. Kaposi's sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells. Proc. Natl. Acad. Sci. U. S. A. 102:5570-5575. http://dx.doi.org/10.1073/pnas.0408192102.
42. Bartel DP. 2009. MicroRNAs: target recognition and regulatory functions. Cell 136:215-233. http://dx.doi.org/10.1016/j.cell.2009.01.002.
43. Gottwein E, Corcoran DL, Mukherjee N, Skalsky RL, Hafner M, Nusbaum JD, Shamulailatpam P, Love CL, Dave SS, Tuschl T, Ohler U, Cullen BR. 2011. Viral microRNA targetome of KSHV-infected primary effusion lymphoma cell lines. Cell Host Microbe 10:515-526. http://dx.doi.org/10.1016/j.chom.2011.09.012.
44. Samols MA, Hu J, Skalsky RL, Renne R. 2005. Cloning and identification of a microRNA cluster within the latency-associated region of Kaposi's sarcoma-associated herpesvirus. J. Virol. 79:9301-9305. http://dx.doi.org/10.1128/JVI.79.14.9301-9305.2005.
45. Hansen A, Henderson S, Lagos D, Nikitenko L, Coulter E, Roberts S, Gratrix F, Plaisance K, Renne R, Bower M, Kellam P, Boshoff C. 2010. KSHV-encoded miRNAs target MAF to induce endothelial cell reprogramming. Genes Dev. 24: 195-205. http://dx.doi.org/10.1101/gad.553410.
46. Seifi A, Weaver EM, Whipple ME, Ikoma M, Farrenberg J, Huang ML, Vieira J. 2011. The lytic activation of KSHV during keratinocyte differentiation is dependent upon a suprabasal position, the loss of integrin engagement, and calcium, but not the interaction of cadherins. Virology 410:17-29. http://dx.doi.org/10.1016/j.virol.2010.10.023.
47. Zhu X, Zhou F, Qin D, Zeng Y, Lv Z, Yao S, Lu C. 2011. Human immunodeficiency virus type 1 induces lytic cycle replication of Kaposi'ssarcoma-associated herpesvirus: role of Ras/c-Raf/MEK1/2, PI3K/AKT, and NF-kappaB signaling pathways. J. Mol. Biol. 410:1035-1051. http://dx.doi.org/10.1016/j.jmb.2011.03.055.
48. Tang Q, Qin D, Lv Z, Zhu X, Ma X, Yan Q, Zeng Y, Guo Y, Feng N, Lu C. 2012. Herpes simplex virus type 2 triggers reactivation of Kaposi's sarcomaassociated herpesvirus from latency and collaborates with HIV-1 Tat. PLoS One 7:e31652. http://dx.doi.org/10.1371/journal.pone.0031652.
49. Qin D, Feng N, Fan W, Ma X, Yan Q, Lv Z, Zeng Y, Zhu J, Lu C. 2011. Activation of PI3K/AKT and ERK MAPK signal pathways is required for the induction of lytic cycle replication of Kaposi's sarcoma-associated herpesvirus by herpes simplex virus type 1. BMC Microbiol. 11:240. http://dx.doi.org/10.1186/1471-2180-11-240.
50. Huang LM, Chao MF, Chen MY, Shih H, Chiang YP, Chuang CY, Lee CY. 2001. Reciprocal regulatory interaction between human herpesvirus 8 and human immunodeficiency virus type 1. J. Biol. Chem. 276:13427-13432. http://dx.doi.org/10.1074/jbc.M011314200.
51. Lefort S, Flamand L. 2009. Kaposi's sarcoma-associated herpesvirus KbZIP protein is necessary for lytic viral gene expression, DNA replication, and virion production in primary effusion lymphoma cell lines. J. Virol. 83:5869-5880. http://dx.doi.org/10.1128/JVI.01821-08.
52. Lei X, Bai Z, Ye F, Xie J, Kim CG, Huang Y, Gao SJ. 2010. Regulation of NF-kappaB inhibitor IkappaBalpha and viral replication by a KSHV microRNA. Nat. Cell Biol. 12:193-199. http://dx.doi.org/10.1038/ncb2019.
53. Wang HW, Trotter MW, Lagos D, Bourboulia D, Henderson S, Makinen T, Elliman S, Flanagan AM, Alitalo K, Boshoff C. 2004. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat. Genet. 36:687-693. http://dx.doi.org/10.1038/ng1384.
54. Qin D, Zeng Y, Qian C, Huang Z, Lv Z, Cheng L, Yao S, Tang Q, Chen X, Lu C. 2008. Induction of lytic cycle replication of Kaposi's sarcomaassociated herpesvirus by herpes simplex virus type 1: involvement of IL-10 and IL-4. Cell. Microbiol. 10:713-728. http://dx.doi.org/10.1111/j.1462-5822.2007.01079.x.
55. Lan K, Kuppers DA, Verma SC, Robertson ES. 2004. Kaposi's sarcomaassociated herpesvirus-encoded latency-associated nuclear antigen inhibits lytic replication by targeting Rta: a potential mechanism for virusmediated control of latency. J. Virol. 78:6585-6594. http://dx.doi.org/10.1128/JVI.78.12.6585-6594.2004.
56. Foreman KE, Friborg J, Jr, Kong WP, Woffendin C, Polverini PJ, Nickoloff BJ, Nabel GJ. 1997. Propagation of a human herpesvirus from AIDS-associated Kaposi's sarcoma. N. Engl. J. Med. 336:163-171. http://dx.doi.org/10.1056/NEJM199701163360302.
57. Lee SB, Park J, Jung JU, Chung J. 2005. Nef induces apoptosis by activating JNK signaling pathway and inhibits NF-kappaB-dependent immune responses in Drosophila. J. Cell Sci. 118:1851-1859. http://dx.doi.org/10.1242/jcs.02312.
58. Ye F, Zhou F, Bedolla RG, Jones T, Lei X, Kang T, Guadalupe M, Gao SJ. 2011. Reactive oxygen species hydrogen peroxide mediates Kaposi's sarcoma-associated herpesvirus reactivation from latency. PLoS Pathog. 7:e1002054. http://dx.doi.org/10.1371/journal.ppat.1002054.
59. Zhou FC, Zhang YJ, Deng JH, Wang XP, Pan HY, Hettler E, Gao SJ. 2002. Efficient infection by a recombinant Kaposi's sarcoma-associated herpesvirus cloned in a bacterial artificial chromosome: application for genetic analysis. J. Virol. 76:6185-6196. http://dx.doi.org/10.1128/JVI.76.12.6185-6196.2002.
60. Vieira J, O'Hearn PM. 2004. Use of the red fluorescent protein as a marker of Kaposi's sarcoma-associated herpesvirus lytic gene expression. Virology 325:225-240. http://dx.doi.org/10.1016/j.virol.2004.03.049.
61. Lin X, Liang D, He Z, Deng Q, Robertson ES, Lan K. 2011. miR-K12-7-5p encoded by Kaposi's sarcoma-associated herpesvirus stabilizes the latent state by targeting viral ORF50/RTA. PLoS One 6:e16224. http://dx.doi.org/10.1371/journal.pone.0016224.
62. Bellare P, Ganem D. 2009. Regulation of KSHV lytic switch protein expression by a virus-encoded microRNA: an evolutionary adaptation that fine-tunes lytic reactivation. Cell Host Microbe 6:570-575. http://dx.doi.org/10.1016/j.chom.2009.11.008.
63. Lu F, Stedman W, Yousef M, Renne R, Lieberman PM. 2010. Epigenetic regulation of Kaposi's sarcoma-associated herpesvirus latency by virusencoded microRNAs that target Rta and the cellular Rbl2-DNMT pathway. J. Virol. 84:2697-2706. http://dx.doi.org/10.1128/JVI.01997-09.
64. Bai Z, Huang Y, Li W, Zhu Y, Jung JU, Lu C, Gao SJ. 2014. Genomewide mapping and screening of Kaposi's sarcoma-associated herpesvirus (KSHV) 3' untranslated regions identify bicistronic and polycistronic viral transcripts as frequent targets of KSHV microRNAs. J. Virol. 88:377-392. http://dx.doi.org/10.1128/JVI.02689-13.
65. Yan Q, Li W, Tang Q, Yao S, Lv Z, Feng N, Ma X, Bai Z, Zeng Y, Qin D, Lu C. 2013. Cellular microRNAs 498 and 320d regulate herpes simplex virus 1 induction of Kaposi's sarcoma-associated herpesvirus lytic replication by targeting RTA. PLoS One 8:e55832. http://dx.doi.org/10.1371/journal.pone.0055832.
66. Parkin DM. 2006. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118:3030-3044. http://dx.doi.org/10.1002/ijc.21731.
67. Sinfield RL, Molyneux EM, Banda K, Borgstein E, Broadhead R, Hesseling P, Newton R, Casabonne D, Mkandawire N, Nkume H, Hodgson T, Liomba G. 2007. Spectrum and presentation of pediatric malignancies in the HIV era: experience from Blantyre, Malawi, 1998-2003. Pediatr. Blood Cancer 48:515-520. http://dx.doi.org/10.1002/pbc.20917.
68. Dittmer DP, Krown SE. 2007. Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus. Curr. Opin. Oncol. 19:452-457. http://dx.doi.org/10.1097/CCO.0b013e3281eb8ea7.
69. Lee HR, Lee S, Chaudhary PM, Gill P, Jung JU. 2010. Immune evasion by Kaposi's sarcoma-associated herpesvirus. Future Microbiol. 5:1349-1365. http://dx.doi.org/10.2217/fmb.10.105.
70. Ye F, Lei X, Gao SJ. 2011. Mechanisms of Kaposi's sarcoma-associated herpesvirus latency and reactivation. Adv. Virol. 2011:193860. http://dx.doi.org/10.1155/2011/193860.
71. Ganem D. 2010. KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J. Clin. Investig. 120:939-949. http://dx.doi.org/10.1172/JCI40567.
72. Liang D, Gao Y, Lin X, He Z, Zhao Q, Deng Q, Lan K. 2011. A human herpesvirus miRNA attenuates interferon signaling and contributes to maintenance of viral latency by targeting IKKepsilon. Cell Res. 21:793-806. http://dx.doi.org/10.1038/cr.2011.5.
73. Lu CC, Li Z, Chu CY, Feng J, Feng J, Sun R, Rana TM. 2010. MicroRNAs encoded by Kaposi's sarcoma-associated herpesvirus regulate viral life cycle. EMBO Rep. 11:784-790. http://dx.doi.org/10.1038/embor.2010.132.
74. Abend JR, Uldrick T, Ziegelbauer JM. 2010. Regulation of tumor necrosis factor-like weak inducer of apoptosis receptor protein (TWEAKR) expression by Kaposi's sarcoma-associated herpesvirus microRNA prevents TWEAK-induced apoptosis and inflammatory cytokine expression. J. Virol. 84:12139-12151. http://dx.doi.org/10.1128/JVI.00884-10.
75. Abend JR, Ramalingam D, Kieffer-Kwon P, Uldrick TS, Yarchoan R, Ziegelbauer JM. 2012. Kaposi's sarcoma-associated herpesvirus microRNAs target IRAK1andMYD88,twocomponentsof the toll-like receptor/interleukin-1R signaling cascade, to reduce inflammatory-cytokine expression. J. Virol. 86:11663-11674. http://dx.doi.org/10.1128/JVI.01147-12.
76. Boss IW, Nadeau PE, Abbott JR, Yang Y, Mergia A, Renne R. 2011. A Kaposi's sarcoma-associated herpesvirus-encoded ortholog of microRNA miR-155 induces human splenic B-cell expansion in NOD/LtSz-scid IL2Rgamma null mice. J. Virol. 85:9877-9886. http://dx.doi.org/10.1128/JVI.05558-11.
77. Dahlke C, Maul K, Christalla T, Walz N, Schult P, Stocking C, Grundhoff A. 2012. A microRNA encoded by Kaposi sarcoma-associated herpesvirus promotes B-cell expansion in vivo. PLoS One 7:e49435. http://dx.doi.org/10.1371/journal.pone.0049435.
78. Gottwein E, Mukherjee N, Sachse C, Frenzel C, Majoros WH, Chi JT, Braich R, Manoharan M, Soutschek J, Ohler U, Cullen BR. 2007. A viral microRNA functions as an orthologue of cellular miR-155. Nature 450: 1096-1099. http://dx.doi.org/10.1038/nature05992.
79. Lei X, Zhu Y, Jones T, Bai Z, Huang Y, Gao SJ. 2012. A Kaposi's sarcoma-associated herpesvirus microRNA and its variants target the transforming growth factor beta pathway to promote cell survival. J. Virol. 86:11698-11711. http://dx.doi.org/10.1128/JVI.06855-11.
80. Liu Y, Sun R, Lin X, Liang D, Deng Q, Lan K. 2012. Kaposi's sarcomaassociated herpesvirus-encoded microRNA miR-K12-11 attenuates transforming growth factor beta signaling through suppression of SMAD5. J. Virol. 86:1372-1381. http://dx.doi.org/10.1128/JVI.06245-11.
81. Nachmani D, Stern-Ginossar N, Sarid R, Mandelboim O. 2009. Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe 5:376-385. http://dx.doi.org/10.1016/j.chom.2009.03.003.
82. Qin Z, Freitas E, Sullivan R, Mohan S, Bacelieri R, Branch D, Romano M, Kearney P, Oates J, Plaisance K, Renne R, Kaleeba J, Parsons C. 2010. Upregulation of xCT by KSHV-encoded microRNAs facilitates KSHV dissemination and persistence in an environment of oxidative stress. PLoS Pathog. 6:e1000742. http://dx.doi.org/10.1371/journal.ppat.1000742.
83. Qin Z, Kearney P, Plaisance K, Parsons CH. 2010. Pivotal advance: Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes. J. Leukoc. Biol. 87:25-34. http://dx.doi.org/10.1189/jlb.0409251.
84. Samols MA, Skalsky RL, Maldonado AM, Riva A, Lopez MC, Baker HV, Renne R. 2007. Identification of cellular genes targeted by KSHV-encoded microRNAs. PLoS Pathog. 3:e65. http://dx.doi.org/10.1371/journal.ppat.0030065.
85. Skalsky RL, Samols MA, Plaisance KB, Boss IW, Riva A, Lopez MC, Baker HV, Renne R. 2007. Kaposi's sarcoma-associated herpesvirus encodes an ortholog of miR-155. J. Virol. 81:12836-12845. http://dx.doi.org/10.1128/JVI.01804-07.
86. Suffert G, Malterer G, Hausser J, Viiliainen J, Fender A, Contrant M, Ivacevic T, Benes V, Gros F, Voinnet O, Zavolan M, Ojala PM, Haas JG, Pfeffer S. 2011. Kaposi's sarcoma herpesvirus microRNAs target caspase 3 and regulate apoptosis. PLoS Pathog. 7:e1002405. http://dx.doi.org/10.1371/journal.ppat.1002405.
87. Ziegelbauer JM, Sullivan CS, Ganem D. 2009. Tandem array-based expression screens identify host mRNA targets of virus-encoded microRNAs. Nat. Genet. 41:130-134. http://dx.doi.org/10.1038/ng.266.
88. Moody R, Zhu Y, Huang Y, Cui X, Jones T, Bedolla R, Lei X, Bai Z, Gao SJ. 2013. KSHV microRNAs mediate cellular transformation and tumorigenesis by redundantly targeting cell growth and survival pathways. PLoS Pathog. 9:e1003857. http://dx.doi.org/10.1371/journal.ppat.1003857.
89. Zhang L, Sullivan PS, Goodman JC, Gunaratne PH, Marchetti D. 2011. MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. Cancer Res. 71:645-654. http://dx.doi.org/10.1158/0008-5472.CAN-10-1910.
90. Lagos D, Pollara G, Henderson S, Gratrix F, Fabani M, Milne RS, Gotch F, Boshoff C. 2010. miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional coactivator. Nat. Cell Biol. 12: 513-519. http://dx.doi.org/10.1038/ncb2054.
91. Kang JG, Majerciak V, Uldrick TS, Wang X, Kruhlak M, Yarchoan R, Zheng ZM. 2011. Kaposi's sarcoma-associated herpesviral IL-6 and human IL-6 open reading frames contain miRNA binding sites and are subject to cellular miRNA regulation. J. Pathol. 225:378-389. http://dx.doi.org/10.1002/path.2962.
92. Punj V, Matta H, Schamus S, Tamewitz A, Anyang B, Chaudhary PM. 2010. Kaposi's sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 suppresses CXCR4 expression by upregulating miR-146a. Oncogene 29:1835-1844. http://dx.doi.org/10.1038/onc.2009.460.